Free Trial Information
BioCentury | Jan 16, 2021
Product Development

Jan. 15 Quick Takes: Darzalex gains first FDA approval for form of amyloidosis; plus Thermo Fisher, Lilly, DBV, Dr. Reddy’s, Alexion, Taiho, Astellas-Actinium

FDA granted accelerated approval to Darzalex Faspro daratumumab/hyaluronidase-fihj from Johnson & Johnson (NYSE:JNJ) and Genmab A/S (CSE:GMAB; NASDAQ:GMAB) to treat newly diagnosed light-chain amyloidosis. It is the first and only therapy for the indication, according to Genmab,...
Read More
BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

...evaluate anti-PCSK9 therapies in combination with checkpoint inhibitors in patients.Amgen Inc. (NASDAQ:AMGN), Astellas Pharma Inc. (Tokyo:4503) and Dr. Reddy's Laboratories Ltd....
Read More
BioCentury | Nov 25, 2020
Product Development

Russia to launch Sputnik V vaccine into global orbit

...V, and plants in China and India have also started manufacturing the vaccine, said Dmitriev. Steve Usdin Dr. Reddy's Laboratories Ltd. AstraZeneca...
Read More
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...region and succeeds Jean-Michel Boers, who is now president and CEO of Boehringer Ingelheim USA Corp. Dr. Reddy's Laboratories Ltd....
...Therapeutics Inc. (NASDAQ:MRTX), Aspen Neuroscience Inc. and Gossamer Bio Inc. (NASDAQ:GOSS). Danielle Golovin Boehringer Ingelheim Horizon Therapeutics plc GlaxoSmithKline plc Dr. Reddy's Laboratories Ltd. Mylan...
Read More
BioCentury | Sep 23, 2020
Deals

Sept. 22 Quick Takes: Celgene CVR still in play; plus Dr. Reddy’s in Sputnik deal, $30M for Siolta, Amgen-Lilly, BioNTech-Novartis, Genentech-Scenic

Priority Review for bluebird-BMS program could fulfill CVR goalFDA’s review timeline for idecabtagene vicleucel (ide-cel, bb2121) from bluebird bio Inc. (NASDAQ:BLUE) and Bristol Myers Squibb Co. (NYSE:BMY) suggests that an approval decision could come before...
Read More
BioCentury | Sep 5, 2020
Product Development

Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis

...AMR-101, LAX-101) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Vamorolone (VBP15) Gilead Sciences Inc. Kite Pharma Inc. HiFiBiO Therapeutics Amarin Corp. plc Dr. Reddy's Laboratories Ltd. Hikma...
Read More
BioCentury | Jul 3, 2020
Deals

July 2 Quick Takes: Novartis to ante up $678M in settlement; plus Zai, Neoleukin, Base Genomics, Sarepta-Hansa, Dr. Reddy-Fujifilm

...mild to moderate COVID-19. BioCentury Staff IdeS, imlifidase Avigan, favipiravir (T-705) Hansa Biopharma AB Sarepta Therapeutics Inc. Zai Lab Ltd. Fujifilm Holdings Corp. Dr. Reddy's Laboratories Ltd. Novartis...
Read More
BioCentury | Mar 31, 2020
Product Development

Amarin set to appeal patent ruling that points way to generic competition for Vascepa

...tied to COVID-19. Paul Bonanos, Associate Editor Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Hikma Pharmaceuticals plc Dr. Reddy's Laboratories Ltd....
Read More
BioCentury | Nov 7, 2019
Product Development

AZ replants R&D roots in China, goes all-in on innovation

In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation. As...
Read More
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
Read More
Items per page:
1 - 10 of 289
BioCentury | Jan 16, 2021
Product Development

Jan. 15 Quick Takes: Darzalex gains first FDA approval for form of amyloidosis; plus Thermo Fisher, Lilly, DBV, Dr. Reddy’s, Alexion, Taiho, Astellas-Actinium

FDA granted accelerated approval to Darzalex Faspro daratumumab/hyaluronidase-fihj from Johnson & Johnson (NYSE:JNJ) and Genmab A/S (CSE:GMAB; NASDAQ:GMAB) to treat newly diagnosed light-chain amyloidosis. It is the first and only therapy for the indication, according to Genmab,...
Read More
BioCentury | Dec 2, 2020
Distillery Therapeutics

Blocking PCSK9 alone or with anti-PD-1 therapies for cancer

...evaluate anti-PCSK9 therapies in combination with checkpoint inhibitors in patients.Amgen Inc. (NASDAQ:AMGN), Astellas Pharma Inc. (Tokyo:4503) and Dr. Reddy's Laboratories Ltd....
Read More
BioCentury | Nov 25, 2020
Product Development

Russia to launch Sputnik V vaccine into global orbit

...V, and plants in China and India have also started manufacturing the vaccine, said Dmitriev. Steve Usdin Dr. Reddy's Laboratories Ltd. AstraZeneca...
Read More
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...region and succeeds Jean-Michel Boers, who is now president and CEO of Boehringer Ingelheim USA Corp. Dr. Reddy's Laboratories Ltd....
...Therapeutics Inc. (NASDAQ:MRTX), Aspen Neuroscience Inc. and Gossamer Bio Inc. (NASDAQ:GOSS). Danielle Golovin Boehringer Ingelheim Horizon Therapeutics plc GlaxoSmithKline plc Dr. Reddy's Laboratories Ltd. Mylan...
Read More
BioCentury | Sep 23, 2020
Deals

Sept. 22 Quick Takes: Celgene CVR still in play; plus Dr. Reddy’s in Sputnik deal, $30M for Siolta, Amgen-Lilly, BioNTech-Novartis, Genentech-Scenic

Priority Review for bluebird-BMS program could fulfill CVR goalFDA’s review timeline for idecabtagene vicleucel (ide-cel, bb2121) from bluebird bio Inc. (NASDAQ:BLUE) and Bristol Myers Squibb Co. (NYSE:BMY) suggests that an approval decision could come before...
Read More
BioCentury | Sep 5, 2020
Product Development

Sept. 4 Quick Takes: HiFiBiO in second cancer deal with Gilead; plus Bridgewest-Pfizer, Amarin, Intercept, Santhera-Idorsia, CMS, Ascendis

...AMR-101, LAX-101) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Vamorolone (VBP15) Gilead Sciences Inc. Kite Pharma Inc. HiFiBiO Therapeutics Amarin Corp. plc Dr. Reddy's Laboratories Ltd. Hikma...
Read More
BioCentury | Jul 3, 2020
Deals

July 2 Quick Takes: Novartis to ante up $678M in settlement; plus Zai, Neoleukin, Base Genomics, Sarepta-Hansa, Dr. Reddy-Fujifilm

...mild to moderate COVID-19. BioCentury Staff IdeS, imlifidase Avigan, favipiravir (T-705) Hansa Biopharma AB Sarepta Therapeutics Inc. Zai Lab Ltd. Fujifilm Holdings Corp. Dr. Reddy's Laboratories Ltd. Novartis...
Read More
BioCentury | Mar 31, 2020
Product Development

Amarin set to appeal patent ruling that points way to generic competition for Vascepa

...tied to COVID-19. Paul Bonanos, Associate Editor Vascepa (amr101, icosapent ethyl, miraxion, AMR-101, LAX-101) Amarin Corp. plc Hikma Pharmaceuticals plc Dr. Reddy's Laboratories Ltd....
Read More
BioCentury | Nov 7, 2019
Product Development

AZ replants R&D roots in China, goes all-in on innovation

In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation. As...
Read More
BioCentury | Oct 19, 2019
Product Development

Tracking the rise and fall of next-generation checkpoint targets for cancer

As the race continues for the next big checkpoint target after PD-1, three candidates are pulling ahead. BioCentury has been following the rise and fall of clinical programs against promising checkpoint proteins since the field...
Read More
Items per page:
1 - 10 of 289